The effects of velvet antler polypeptides on the phenotype and related biological indicators of osteoarthritic rabbit chondrocytes

Zhengyao Zhang1,*, Xiaofeng Liu2,*, Lengxin Duan3, Xia Li1, Yang Zhang1,2, and Qiuli Zhou1,2

1Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, Jilin, P.R. China; 2Clinical Laboratory of Tumor Hospital of Jilin Province, Jilin, P.R.China; 3Department of Pharmacology, Henan University of Science and Technology, Henan, P.R. China

Abstract: To study the effects of velvet antler polypeptides (VAPs) on osteoarthritic chondrocytes (OCs) in rabbits. Methods: An osteoarthritic rabbit model was established according to Hulth’s method. OCs were isolated and cultured for observation of the cell cycle. Cell proliferation was detected by MTT assay and the cell cycle was monitored by flow cytometry. The phenotype was determined by toluidine blue staining as well as immunohistochemical staining for collagen type II. The expression of MMP-1, MMP-3, MMP-13, TIMP-1, and collagen I and X mRNA by chondrocytes was assayed by RT-PCR. Results: The VAPs had no obvious proliferative effect on OCs and did not affect the cell cycle. Moreover, they significantly reduced the proportion of early apoptotic cells in a dose-dependent manner. Further, VAPs inhibited the expression of collagen I and X mRNA and induced abnormal expression of MMP-1 and MMP-13 mRNA. VAPs had no significant effect on MMP-3 and TIMP-1 mRNA levels. The toluidine blue and collagen type II immunohistochemical staining intensities of VAP-treated chondrocytes were positively correlated with the concentration of VAPs used. Conclusion: VAPs had no significant effect on OC proliferation and the cell cycle, but did increase the glycosaminoglycan (GAG) and collagen type II expression levels in the extracellular matrix, and down-regulated collagen I and X mRNA expression. Treatment of cartilage cells with VAPs maintained their normal phenotype, inhibited matrix metalloproteinases (MMPs) secretion, kept the balance of cartilage matrix metabolism, and sustained an external environment where the cartilage cells could survive. Moreover, VAPs reduced the proportion of early apoptotic cells, suggesting that they may block the apoptotic pathway in OCs.

Keywords: velvet antler polypeptides, osteoarthritic chondrocytes, apoptosis, MMP

Received: 11 November, 2010; revised: 12 May, 2011; accepted: 03 July, 2011; available on-line: 11 July, 2011

INTRODUCTION

Velvet antlers have several pharmacological properties and have been used in the clinical treatment of many diseases. Velvet antler polypeptides (VAPs) (have been found to regulate immune activities and have anti-oxidant properties (Kim et al., 2003). Studies have shown that osteoarthritis can be effectively treated with VAPs (Kim et al., 2005; 2008). Another study has also shown that the incidence of osteoarthritis is closely related to the pathology of chondrocytes (Kraan et al., 2009). In addition, it has been reported that VAPs have an effect on the proliferation of normal cartilage cells in rabbits (Guo et al., 1998; Qu & Kang, 2000). In this study, we investigated the effects of VAPs on osteoarthritic chondrocytes (OCs) to clarify the pathogenesis of osteoarthritis and to provide an experimental basis for the clinical application of VAPs.

MATERIALS AND METHODS

Experimental animals. The Laboratory Animal Center of Bethune Medical College of Jilin University (Certificate of Quality No. 0024494) provided 24 Japanese, big-ear white rabbits that were 5 months old (12 males and 12 females) and 2.0–2.5 kg in weight.

Reagents. Our research group purified VAPs (Duan, 2007) and commercially obtained the following reagents: MTT (Amresco Inc., USA), Cell Apoptosis PI Detection Kit (KeyGEN, China), Annexin V-FITC Apoptosis Detection Kit (KeyGEN), toluidine blue, 1,9-dimethyl methylene blue, and type II collagenase (Sigma-Aldrich, USA), collagen II antibody (Neomarkers Inc., USA), SP and DAB kits (Maixin, China), reverse transcription kit (MBI Inc., USA), Taq and the DL2000 marker (Takara, Japan), IMDM (Gibco, USA), FBS (HyClone Inc., USA), trypsin (Dingguo, China), and dimethyl sulfoxide (DMSO) (Beijing Chemical Plant, China).

Instruments. The following instruments were used in this study: an automatic microplate reader (TECAN, Austria), CO2 incubator (Thermo Scientific 3110, USA), flow cytometer (BD Biosciences, USA), optical microscope (Olympus PM2, Japan), inverted microscope (CK type, Olympus), spectrophotometer (Ascent, China), constant temperature water bath (Yiheng Experimental Instrument Co., Ltd., China), and Image-Pro image analysis software (http://www.mediacy.com/index.aspx?page=Image_Pro_Software).

Establishment of osteoarthritis model in rabbits and isolation and culturing of chondrocytes. The
24 rabbits were divided into 8 groups of 3 rabbits each. One rabbit from each group underwent a sham operation, and the other 2 were used for the osteoarthritis model, according to the method by Hulth et al. (Liu et al., 2005). One group of models was created every week for 8 weeks. On the 9th week and thereafter, one group of animals was selected for the isolation and culturing of chondrocytes every week.

To isolate chondrocytes, the knee of each rabbit was isolated, rinsed, and immersed in sterile D-Hank’s solution. The articular cartilage was then isolated from the patellar and collateral ligaments, rinsed, and ground to 1 mm² sections in D-Hank’s solution. The tissue was then digested with 0.25% trypsin containing 0.04% EDTA and incubated at 37°C for 30 min. The trypsin was then removed and Type II collagen was added. The cells were finally incubated at 37°C for 4 h, filtered, and centrifuged. Iscove’s modified Dulbecco’s medium (IMDM) containing 10% FBS (fetal bovine serum) was used for cell culture. After cell adherence, different concentrations of VAPs (6.25, 12.5, and 25.0 μg/mL) were added to the culture medium, and the related biological markers were examined for the next 8 weeks. The following cell groups were established: a control group, for which cells were isolated from the sham-operated rabbits and cultured in media alone; a model group, for which cells were isolated from the osteoarthritic rabbit model group and cultured in media; a low-dose VAP group, for which 6.25 μg/mL of VAPs was added to the cells from the model group during culture; a moderate-dose VAP group, for which 12.5 μg/mL of VAPs was added; and a high-dose VAP group, for which 25 μg/mL of VAPs was added.

Determination of proliferation by the MTT assay. For the MTT assay, 5 × 10⁴/mL chondrocytes were seeded in 96-well plates, with each well containing 0.1 mL of the cell suspension. After cell adherence, 0.2 mL of VAPs was added to each well and the cells were cultured for 48 h, MTT (5 mg/mL) was added to each well. After 4 h of incubation, the medium was removed and 100 μL DMSO was added to resuspend the MTT metabolic product. The absorbance was measured at 570 nm.

Cell cycle analysis by flow cytometry. Four mL of 5 × 10⁴/mL chondrocytes from each group were seeded in 25 cm² culture flasks. After cell adherence, 1 mL of VAPs was added to each flask and the cells were cultured for 48 h. The cells were then digested with 0.25% trypsin, collected, and fixed with 70% ice-cold ethanol for PI single staining. Flow cytometry was used to detect changes in the cell cycle.

Detection of glycosaminoglycans (GAG) and collagen type II in chondrocytes. In order to culture cells on coverslips, 5 × 10⁴/mL chondrocytes from each group of cell seeded in 6-well plates with a single coverslip placed in each well. Each well received 2 mL suspension. After cell adherence, 1 mL of VAPs was added to each well and the cells were cultured for 48 h. The cells were then fixed with 4% paraformaldehyde for (1) determination of the phenotype by toluidine blue staining and (2) immunohistochemical staining of collagen type II.

Detection of the expression of MMP-1, MMP-3, MMP-13, TIMP-1, and collagen I and X mRNA in chondrocytes. Four mL of 5 × 10⁴/mL chondrocytes from each group were seeded in 25 cm² culture flasks. After cell adherence, 1 mL of VAPs was added into each flask and the cells were cultured for 48 h. Total RNA was extracted with Trizol reagent (Invitrogen) and cDNA was synthesized by RT-PCR. The primers used are listed in Table 4. Briefly, 1 μg RNA, 1 μl oligo(dT), and 0.1% DEPC ddH₂O to a final volume of 12 μl were mixed and incubated at 70°C for 5 min. The sample was then immediately placed on ice and vortexed after being cooled. After vortexing, 4 μl 5× reaction buffer, 1 μl RNA inhibitor, and 2 μl of a dNTP mixture were added and incubated at 37°C for 5 min. One microliter of reverse transcriptase was then added and the total reaction volume was 20 μl. For RT-PCR, the sample was incubated at 42°C for 60 min followed by 70°C for 10 min to inactivate reverse transcriptase, and then placed on ice. The following PCR conditions were then used: 2 μl 10× Taq buffer, 2 μl dNTP, 1 μl of each primer, 1 μl Taq polymerase, 1.2 μl MgCl₂ solution, 1 μl template cDNA, and ddH₂O to a final volume of 20 μl. The PCR cycles used were: 94°C for 30 s, followed by 55°C for 30 s and 72°C for 30 s. The last extension was at 72°C for 10 min. Samples were analyzed by 1% agarose gel electrophoresis. The expression level of the

<table>
<thead>
<tr>
<th>Table 1. Effects of VAPs on OC proliferation (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
</tr>
<tr>
<td>Control</td>
</tr>
<tr>
<td>Model</td>
</tr>
<tr>
<td>6.25 μg/mL VAPs</td>
</tr>
<tr>
<td>12.5 μg/mL VAPs</td>
</tr>
<tr>
<td>25.0 μg/mL VAPs</td>
</tr>
</tbody>
</table>

Note: *P<0.05 vs. control.
various genes was analyzed on an imaging system with β-actin used as a reference.

**Detection of early apoptosis in chondrocytes.** Flow cytometry analysis was used to determine the level of apoptosis, 5 × 10⁴/mL chondrocytes from each group were seeded in 6-well plates, with 2 mL of suspension in every well. After cell adherence, 1 mL of VAPs was added to each flask and the cells were cultured for 48 h. The cells were digested with 0.25% trypsin and collected for annexin V-PI double staining and incubated for 10 min at 15 °C in the dark. The data were analyzed with Becton Dickinson CELLQuest software.

**Statistical and image analysis.** The EXCEL statistical software, ANOVA, and Student’s t-test were used for statistical analysis. Immunohistochemical staining was analyzed using Image-Pro image analysis software. In accordance with the 5-point sampling method, the images of 4 sections in each experimental group under the same magnification were randomly collected for gray-scale analysis. The positive target area was calculated and divided by the total area of vision to obtain the average area density of positive action. Image and quantitative analyses were conducted for mRNA expression by using the Tanon GIS-2020 gel imaging system.

**RESULTS**

**Effect of VAPs on proliferation of OCs**

The MTT test results are shown in Table 1. Compared with the control group, the model group exhibited significantly higher proliferation of OCs, indicating that the newly isolated OCs retained their characteristics after phenotype determination. The VAPs slightly accelerated the cell proliferation of every group, whereas no significant difference was detected, suggesting that VAPs have a limited effect in promoting cell proliferation.

**Effect of VAPs on the OC cell cycle**

Table 2 and Fig. 1 show that the model group exhibited a slightly lower proportion of G₁/G₀-M and S-phase cells (P<0.01) compared to the control group. However, no significant difference was observed in cells treated with different concentrations of VAPs as compared with control. Thus, VAPs did not play any obvious regulatory role on the OC cell cycle. This finding was consistent with the results of the proliferation test.

**Effect of VAPs on early apoptosis of chondrocytes**

As shown in Table 3 and Fig. 2, the model group exhibited a significantly higher proportion of early apoptotic cells (P<0.001) compared to the control group. The VAPs significantly reduced the proportion of early apoptotic cells in a dose-dependent manner, suggesting that they inhibit early apoptosis of chondrocytes and confer a protective effect on chondrocytes.

**Effect of VAPs on MMP-1, MMP-3, MMP-13, TIMP-1, and collagen I and X mRNA expression in chondrocytes**

VAPs inhibited the expression of collagen I and X mRNA, and lowered the abnormal expression of MMP-1 and MMP-13 mRNA (Fig. 3). They had no marked effect on the MMP-3 and TIMP-1 mRNA levels. These results suggest that VAPs can inhibit the abnormally high expression of collagen and thereby

---

**Table 2. Effects of VAPs on the cell cycle of OCs (n=3)**

<table>
<thead>
<tr>
<th>Group</th>
<th>G₁/G₀ (%)</th>
<th>G₁-M (%)</th>
<th>S (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>76.41 ± 2.40</td>
<td>14.99 ± 2.39</td>
<td>8.60 ± 1.76</td>
</tr>
<tr>
<td>Model</td>
<td>66.71 ± 2.12**</td>
<td>19.96 ± 1.53*</td>
<td>13.33 ± 2.34*</td>
</tr>
<tr>
<td>6.25 µg/mL VAPs</td>
<td>64.93 ± 1.46</td>
<td>20.97 ± 2.07</td>
<td>14.10 ± 2.48</td>
</tr>
<tr>
<td>12.5 µg/mL VAPs</td>
<td>64.90 ± 2.90</td>
<td>19.70 ± 3.32</td>
<td>13.59 ± 2.92</td>
</tr>
<tr>
<td>25.0 µg/mL VAPs</td>
<td>65.05 ± 4.95</td>
<td>20.30 ± 3.67</td>
<td>14.65 ± 1.45</td>
</tr>
</tbody>
</table>

Note: *P<0.05, **P<0.01 vs. control

**Table 3. Effects of VAPs on early apoptosis of OCs (n=3)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Apoptosis (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>4.74 ± 0.30</td>
</tr>
<tr>
<td>Model</td>
<td>10.29 ± 0.39***</td>
</tr>
<tr>
<td>6.25 µg/mL VAPs</td>
<td>9.08 ± 0.60*</td>
</tr>
<tr>
<td>12.5 µg/mL VAPs</td>
<td>6.82 ± 0.56**</td>
</tr>
<tr>
<td>25.0 µg/mL VAPs</td>
<td>5.72 ± 0.43**</td>
</tr>
</tbody>
</table>

Note: ***P<0.001 vs. control; *P<0.05, **P<0.001 vs. model
Z. Zhang and others contribute to the retention of the chondrocyte phenotype. In addition, VAPs can simultaneously lower the high expression of some degradation enzymes, thereby partially inhibiting the excessive degradation of the cartilage matrix.

Effect of VAPs on the OC phenotype

Under a light microscope, chondrocytes from the control group were strongly stained with toluidine blue, while those from the model group were unstained. The toluidine blue staining deepened with an increase in the VAPs concentration (Fig. 4I), indicating that the GAG levels in the chondrocytes gradually

Figure 3. Effects of VAPs on MMP-1, MMP-3, MMP-13, TIMP-1, and collagen I and X mRNA expression by chondrocytes

VAPs inhibited the expression of collagen I and X mRNA as well as the abnormal expression of MMP-1 and MMP-13 mRNA. They had no significant effect on MMP-3 and TIMP-1 mRNA levels. The results were quantified based on three experiments and are presented as means ± S.D. **P<0.01 vs. control; *P<0.05, and *P<0.01 vs. model group.

Figure 4. Effects of VAPs on the OC phenotype

Collagen II staining was observed under inverted microscope. (I) Toluidine blue staining of cartilage (200×). Toluidine blue staining of cartilage (200×). Immunohistochemical staining for collagen type II in OCs (200×). Immunohistochemical staining for collagen type II in chondrocytes showed that the staining was weakly positive, and for the model group the area of positive staining was significantly smaller than of the control group. After treatment with VAPs at different concentrations, the immunohistochemical staining for collagen II gradually intensified, indicating that the collagen II level in the cells had recovered. ** **P<0.001 vs. control; *P<0.05, *P<0.001 vs. model group.
increased with the increasing concentration of VAPs. These results suggested that although VAPs do not seem to have a clear regulatory role in the proliferation of chondrocytes, they promote the maintenance of the normal phenotype of chondrocytes.

The immunohistochemical staining for collagen type II in the chondrocytes is shown in Fig. 4II. In the model group, the staining was weakly positive, and the area of positive staining was markedly smaller than that of the control group. After treatment with VAPs at different concentrations, the immunohistochemical staining for collagen II gradually intensified, indicating that the collagen II level in the cells had recovered. Collagen type II is the characteristic collagen of hyaline cartilage. These results suggest that VAPs assist in maintaining normal collagen secretion of chondrocytes as well as a normal phenotype.

**DISCUSSION**

Osteoarthritic chondrocytes (OCs) play a major role in osteoarthritis, which is a common chronic joint disease in the elderly that causes significant pain and disability. Previous studies had shown that VAPs can promote the proliferation of normal chondrocytes, but the effects of VAPs on OCs proliferation were not clear. One possibility is that in the active proliferative state, the regulatory factors of OCs dominantly control proliferation, and therefore the OCs are insensitive to VAPs. Alternatively, since the VAPs were dissolved in medium containing 10% serum in those studies, serum growth factors may have masked the proliferation-promoting effects of VAPs.

Collagen type II is the characteristic matrix component produced by chondrocytes. Collagen types I and III are predominantly secreted by fibroblasts. Collagen X is produced by hypertrophic chondrocytes (Von Der Mark et al., 1992). Histologically, OCs is characterized by cartilage fibrillation, collagen II degeneration, aggrecan loss, blood vessel invasion, chondrocyte hypertrophy, and cartilage calcification (Gauci et al., 2008). In a previous study, OCs showed phenotypic changes, as indicated by the increased expression of collagens I, III, and X as well as decreased expression of collagen II (Guo et al., 2003). Our results are in agreement with those previous results. Therefore, although the OCs were in an active state of proliferation, phenotypic changes caused their differentiation toward fibrochondrocytes or hypertrophic chondrocytes rather than normal cartilage tissue. Due to the constant stimulation by damaging factors and abnormal results caused by compensatory restoration coupled with enhanced catabolism, the cartilage structure was gradually destroyed, and osteoarthritis became more severe. VAPs can increase the GAG and collagen II levels in chondrocytes, and reduce the level of collagen I and X mRNA. Thus, VAPs may repair the early damage of cartilage and delay the progression of osteoarthritis.

Since the metabolism and catabolism of normal cartilage matrix are in balance, the structure, form, and function of normal cartilage are maintained. Increased MMP expression can be detected in the early stages of osteoarthritis (Pelletier, 1990). When the increased compensatory synthesis of cartilage matrix and cell proliferation cannot offset the loss of the extracellular matrix due to catabolism, chondrocyte apoptosis occurs as a result of the unstable internal environment, and this is the direct cause for cartilage loss in the intermediate and advanced stages of osteoarthritis. VAPs inhibit the overexpression of some MMPs by chondrocytes, which helps maintain the cartilage matrix metabolic balance and protect cartilage.

Most normal chondrocytes are in the resting period, and the proportion of apoptotic cells is low (Aigner et al., 2001). The increase in the number of apoptotic chondrocytes is the main cause of chondrocyte loss (Kim et al., 2000). An important role of apoptosis in OCs has been demonstrated in both in vitro and in vivo models. However, it should be noted that the relative contribution of apoptotic cell death in the pathogenesis of osteoarthritis is still difficult to assess, due to the chronic nature of the disease. The death receptor, mitochondrial, and endoplasmic reticulum pathways are the major cellular pathways involved in apoptosis (Kim & Blanco, 2007). In the early stages of osteoarthritis, the ratio of apoptotic chondrocytes increases significantly, suggesting that the apoptotic pathway is initiated in chondrocytes by damaging factors. VAPs can inhibit the increase in the number of early-apoptotic chondrocytes, and therefore may block apoptosis in chondrocytes and protect them from cell death. This study has shown that VAPs have effects on the phenotype, MMP secretion, and apoptosis of chondrocytes, indicating that VAPs can have a substantial therapeutic effect in osteoarthritis.

**Acknowledgement**

This work was supported by the National Natural Science Foundation of China, grant No. 30472224, and was supported by the Fundamental Research Foundation of Jilin University, grant No. 201103232.
REFERENCES


